AN2 Therapeutics Grants Equity to Two New Employees
AN2 Therapeutics awarded stock options and restricted stock units to two newly hired employees as inducement grants permitted by Nasdaq rules. The options cover 10,565 shares with a $3.37 exercise price, while 5,283 RSUs were also granted. The awards vest over four years, subject to continued service.
AN2 Therapeutics is a Menlo Park, California-based drug developer traded on Nasdaq under ANTX. Its compensation committee approved the hiring-related awards on October 19, 2026, using the company’s 2026 Employment Inducement Award Plan and Nasdaq’s exception for inducement grants.
The options’ strike price equaled the October 19 closing value of $3.37 on the Nasdaq Global Market. A quarter of the options vests after one year, then monthly; the RSUs vest once yearly over four years. Recipients must stay employed for the awards to vest.
The awards may give the two new hires a longer-term stake in AN2’s performance, potentially supporting retention as small drug developers compete for specialized staff. Existing shareholders could face limited dilution if the options are exercised or RSUs vest, though the grant size appears small. More broadly, such hiring-linked equity may influence how biotech employees weigh compensation against vesting risk and job stability.